Collectively Answering the Venetoclax BTK Inhibitor Sequencing Question in CLL.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 32366672.
- Also identified by DOI 10.1158/1078-0432.CCR-20-1035.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Whether BTK inhibitors are effective when used after venetoclax in patients with chronic lymphocytic leukemia is an important unanswered question. In a large retrospective cohort study examining outcomes for next line treatment after venetoclax, BTK inhibitors were found to result in durable responses in patients who were not previously BTK inhibitor resistant.<i>See related article by Mato et al., p. 3589</i>.
Medical subject headings
- Leukemia, Lymphocytic, Chronic, B-Cell